

What is claimed is:

1. A method of treating a corticosteroid-responsive disease of the upper, or lower airway passages or of the lungs in patients afflicted with said disease, which comprises administering once-a-day to the surfaces of said passages or lungs of said patients a substantially non-systematically bioavailable amount of aerosolized particles of mometasone furoate effective for treating said disease.
2. The method of claim 1 wherein the disease is allergic or nonallergic rhinitis of the upper airway passages.
3. The method of claim 1 wherein the disease is an allergic or inflammatory disease of the lower airway passages and/or lungs.
4. The method of claim 1 wherein the disease is asthma.
5. A method of treating allergic or non-allergic rhinitis in patients afflicted with said rhinitis which comprises administering once-a-day to the surfaces of the upper airway passages of said patients an amount of aerosolized particles of mometasone furoate effective to maximize topically treating said rhinitis in the upper airway passages while simultaneously substantially minimizing systemic bioavailability thereof.
6. The method of claim 5 wherein the mometasone furoate is administered intranasally.

7. The method of claim 5 wherein the amount of mometasone furoate administered is in the range of about 25 to about 800 micrograms/day.
- 5 8. The method of claim 5 wherein the mometasone furoate is administered in the form of an aqueous suspension.
9. A method of treating allergic and/or inflammatory diseases of the lower airway passages and/or lung in patients afflicted with at least one  
10 of said diseases which comprises administering once-a-day via oral administration to the surfaces of the upper and lower airway passages of said patients an amount of mometasone furoate effective to maximize topically treating said allergic and/or inflammatory diseases in the lower airway passage and/or lungs while simultaneously substantially minimizing  
15 the systemic bioavailability thereof.
10. The method of claim 9 wherein the disease treated is an inflammatory disease.
- 20 11. The method of claim 9 wherein the inflammatory disease treated is a inflammatory disease associated with chronic obstruction pulmonary disease.
12. The method of claim 9 wherein the disease treated is a  
25 granulomatous disease of the lungs, and upper and lower airway passages.
13. The method of claim 9 wherein the disease treated is a non-malignant proliferative and/or inflammatory disease of the lungs.

14. The method of claim 13 wherein the non-malignant proliferative and/or inflammatory disease of idiopathic pulmonary fibrosis.
15. The method of claim 9 wherein the diseased treated is  
5 bronchoplumunary dysphasia.
16. The method of claim 9 wherein the disease treated is hypersensitivity pneumonitis.
- 10 17. The method of claim 9 wherein the (inflammatory) amount of mometasone furoate administered is in the range of about 10 to about 5000 micrograms/days.
- 15 18. A method of treating asthma in a patient afflicted with asthma which comprises administering once-a-day to the surfaces of the lower airway passages and lungs of the patient an amount of aerosolized particles of mometasone furoate effective to maximize treating asthma in the lower airway passages and lungs while simultaneously substantially minimizing systemic bioavailablity thereof.
- 20 19. The method of claim 18 wherein the amount of mometasone furoate administered is in the range of about 50 to about 1000 micrograms/day.
- 25 20. The method of claim 18 wherein the mometasone furoate is administered by oral inhalation.

21. The method of claim 20 wherein a metered dose inhaler is used to administer the mometasone furoate in the amount of about 50 to about 1000 micrograms a day.
- 5 22. The method of claim 20 wherein a dry powder inhaler is used to administer the mometasone furoate in the amount of 100 to 600 micrograms a day.
23. The method of claim 19 wherein the mometasone furoate is  
10 intranasally administered.
24. The method of claim 23 wherein the mometasone furoate is administered intranasally in the form of an aqueous suspension.
- 15 25. A method of producing a rapid onset of action in treating asthma in patients afflicted with asthma which comprises administering via oral inhalation to the lower airway passages and lungs of said patients a non-systematically bioavailable amount of aerosolized particles of mometsone furoate effective for producing said accelerated onset of action.  
20
26. The method of claim 25 wherein a metered dose inhaler is used to administer the mometasone furoate in the dosage range of 50 to 1000 mcg/day.
- 25 27. The method of claim 25 wherein a dry powder inhaler is used to administer the mometasone furoate.
28. The method of claim 25 wherein the mometasone furoate is administered in a range of about 100 to 600 mcg/day.

29. The method of claim 25 wherein the mometasone furoate is administered in admixture with lactose.